Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571480 | 1.00 | ITGB1 (0.89) | ITGB1ITGA4 | |
| SCHEMBL14263692 | 0.94 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL13437466 | 0.94 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL12863716 | 0.94 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL14254439 | 0.92 | ITGB1 (0.87) | ITGB1ITGA4 | |
| SCHEMBL14254446 | 0.92 | ITGB1 (0.87) | ITGB1ITGA4 | |
| SCHEMBL13462334 | 0.92 | ITGB1 (0.86) | ITGB1ITGA4 | |
| SCHEMBL3575873 | 0.92 | ITGB1 (0.86) | ITGB1ITGA4 | |
| SCHEMBL14254458 | 0.92 | ITGB1 (0.86) | ITGB1ITGA4 | |
| SCHEMBL24945374 | 0.92 | ITGA4 (0.86) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665322-A1 | DYSREGULATION OF PLANKTONIC BACTERIAL METABOLISM | Neolixir Limited (AU) | 2025-12-24 | — | — | EP | disclosed |
| US-12419619-B2 | Aspiration device | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240397944-A1 | METHODS FOR BIOFILM DISRUPTION | Lixa Limited (AU) | 2024-12-05 | — | — | US | disclosed |
| WO-2024229525-A1 | DYSREGULATION OF PLANKTONIC BACTERIAL METABOLISM | Neolixir Limited (AU) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429651-A1 | METHODS FOR BIOFILM DISRUPTION | Neolixir Limited (AU) | 2024-09-18 | — | — | EP | disclosed |
| CN-118251216-A | Method for biofilm disruption | 尼尔利希尔有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4360567-A2 | ASPIRATION DEVICE | Yale University (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3528709-B1 | ASPIRATION DEVICE | UNIV YALE (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | GLAS USA LLC | 2023-10-05 | — | — | US | disclosed |
| WO-2023081974-A1 | METHODS FOR BIOFILM DISRUPTION | Neolixir Pty Ltd (AU) | 2023-05-19 | — | — | WO | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230045633-A1 | METHOD FOR REDUCING LUNG INFLAMMATION | Respirion Pharmaceuticals Pty Ltd (AU) | 2023-02-09 | — | — | US | disclosed |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | GLAS USA LLC | 2023-02-09 | — | — | US | disclosed |
| US-11491126-B2 | Method for reducing lung inflammation | Respirion Pharmaceuticals Pty Ltd (AU) | 2022-11-08 | — | — | US | disclosed |
| US-11382884-B2 | Method for reducing lung infection | Respirion Pharmaceuticals Pty Ltd (CA) | 2022-07-12 | — | — | US | disclosed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | FABP2, IL2, TSLP | ITGB1 2828/4885ITGA4 1312/4885 |
| US-20240397944-A1 | METHODS FOR BIOFILM DISRUPTION | FGB, MMP8, HAO2 | ITGB1 142/4885ITGA4 351/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | ITGB1 3708/4885ITGA4 3409/4885 |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | TNF, TNFRSF1A, FABP2 | ITGB1 3963/4885ITGA4 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.